Researchers demonstrated that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA was required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity.
[Cancer Immunology Immunotherapy]
